Drug profile · INN
denileukin diftitox
ONTAK
denileukin diftitox (ONTAK) is a interleukin-2 receptor binding agent. Current US regulatory status: approved.
FDA: approved
US status approved
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — denileukin diftitox
- US status
- approved
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 2
- Data quality
- 0.81
Quick answer
denileukin diftitox (ONTAK) is a interleukin-2 receptor binding agent. Current US regulatory status: approved.
Key facts
INN denileukin diftitox
Brand ONTAK
Mechanism Interleukin-2 receptor binding agent
Target Elongation factor 2
Formulation VIAL
Mechanism of action
Interleukin-2 receptor binding agent
Primary target: Elongation factor 2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is denileukin diftitox?
denileukin diftitox (ONTAK) is a interleukin-2 receptor binding agent. Current US regulatory status: approved.
What is the brand name for denileukin diftitox?
ONTAK is a marketed brand name for denileukin diftitox. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of denileukin diftitox?
denileukin diftitox has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.